Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • tenecteplase
Tenecteplase Improves 90-Day Functional Outcomes in Basilar Artery Occlusion Within a 24-Hour Window: Results from TRACE-5
Posted inNeurology news

Tenecteplase Improves 90-Day Functional Outcomes in Basilar Artery Occlusion Within a 24-Hour Window: Results from TRACE-5

Posted by MedXY By MedXY 02/16/2026
The TRACE-5 trial demonstrates that tenecteplase significantly improves functional outcomes for patients with basilar artery occlusion within 24 hours of onset, offering a safe and effective extension of the therapeutic window for this high-mortality condition.
Read More
Expanding the Thrombolysis Window: Tenecteplase Improves Outcomes in Late-Window Non-Large Vessel Occlusion Stroke
Posted inNeurology news Radiology

Expanding the Thrombolysis Window: Tenecteplase Improves Outcomes in Late-Window Non-Large Vessel Occlusion Stroke

Posted by MedXY By MedXY 02/08/2026
The OPTION trial reveals that tenecteplase administered 4.5 to 24 hours post-stroke in patients with non-large vessel occlusion and salvageable tissue significantly improves functional recovery, although it carries a higher risk of symptomatic intracranial hemorrhage compared to standard care.
Read More
Tenecteplase Fails to Improve Visual Outcomes in Acute Central Retinal Artery Occlusion: Results from the TenCRAOS Trial
Posted inNeurology news Ophthalmology

Tenecteplase Fails to Improve Visual Outcomes in Acute Central Retinal Artery Occlusion: Results from the TenCRAOS Trial

Posted by MedXY By MedXY 02/02/2026
The TenCRAOS trial demonstrated that intravenous tenecteplase administered within 4.5 hours of acute central retinal artery occlusion does not improve vision recovery compared to aspirin and carries significant safety risks, including fatal intracranial hemorrhage.
Read More
Tenecteplase Outperforms Alteplase in Mechanical Heart Valve Thrombosis: Insights from the TENET Trial
Posted inCardiology news

Tenecteplase Outperforms Alteplase in Mechanical Heart Valve Thrombosis: Insights from the TENET Trial

Posted by MedXY By MedXY 01/16/2026
The TENET randomized clinical trial reveals that tenecteplase bolus administration achieves significantly higher thrombolytic success rates and shorter hospital stays compared to alteplase infusion for mechanical prosthetic valve thrombosis, potentially redefining the standard of care.
Read More
Reevaluating Intravenous Tenecteplase in Minor Disabling Stroke: Insights from the TEMPO-2 Secondary Analysis
Posted inNeurology news

Reevaluating Intravenous Tenecteplase in Minor Disabling Stroke: Insights from the TEMPO-2 Secondary Analysis

Posted by MedXY By MedXY 10/29/2025
A secondary analysis of the TEMPO-2 trial shows that intravenous tenecteplase does not improve 90-day outcomes in minor disabling stroke defined by NIHSS scores, highlighting the need to reconsider thrombolysis in this patient population.
Read More
Tenecteplase in Modern Stroke Care: Comparative Insights from Recent Chinese Clinical Trials
Posted inNeurology Specialties

Tenecteplase in Modern Stroke Care: Comparative Insights from Recent Chinese Clinical Trials

Posted by MedXY By MedXY 08/01/2025
Three major Chinese trials examine intravenous and intra-arterial tenecteplase as adjuncts to thrombectomy in acute large-vessel occlusion stroke, revealing functional benefit with intravenous use before thrombectomy but not after reperfusion.
Read More
Intra-arterial Tenecteplase After Thrombectomy for Acute Stroke: Interpreting the ANGEL-TNK Randomized Clinical Trial
Posted inClinical Updates Neurology news Specialties

Intra-arterial Tenecteplase After Thrombectomy for Acute Stroke: Interpreting the ANGEL-TNK Randomized Clinical Trial

Posted by MedXY By MedXY 07/31/2025
The ANGEL-TNK trial found that intra-arterial tenecteplase after successful endovascular thrombectomy improved excellent neurological outcomes at 90 days without increasing bleeding or mortality, but secondary outcomes showed no significant benefit.
Read More
Intra-arterial Tenecteplase After Thrombectomy for Acute Stroke: Interpreting the ANGEL-TNK Randomized Clinical Trial
Posted inClinical Updates news

Intra-arterial Tenecteplase After Thrombectomy for Acute Stroke: Interpreting the ANGEL-TNK Randomized Clinical Trial

Posted by MedXY By MedXY 07/31/2025
The ANGEL-TNK trial found that intra-arterial tenecteplase after successful endovascular thrombectomy improved excellent neurological outcomes at 90 days without increasing bleeding or mortality, but secondary outcomes showed no significant benefit.
Read More
  • Sentinel Lymph Node Biopsy in Head and Neck Merkel Cell Carcinoma: Why High False-Negative Rates Demand Clinical Vigilance
  • Head and Neck Metastases From Infraclavicular Primary Tumors: Analysis of 136 Cases
  • Comparative Economic and Clinical Analysis of Robotic, Laparoscopic, and Open Approaches in Hepatopancreatic Surgery
  • Minimally Invasive Surgery Reduces Hospital Charges in Hepatopancreatic Resection: Challenging the Perception of High Robotic Costs
  • The Socio-Clinical Impact of Medicaid Expansion on Pancreatic Cancer Survival: Evidence from a Multi-State Longitudinal Analysis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in